Intellia's Phase 3 CRISPR Therapy Cuts HAE Attacks by 87%, Advancing Regulatory Path

Intellia Therapeutics (NASDAQ: NTLA) released new Phase 3 clinical data for lonvo-z, its one-time CRISPR-based gene editing therapy for hereditary angioedema (HAE), showing an 87% reduction in HAE attacks. The readout, disclosed via a Regulation FD filing on June 15, 2026, reinforced the company's regulatory outlook. NTLA shares gained 4.47% on Wednesday, June 17, 2026, closing at $15.20.

Phase 3 lonvo-z Data

• 87% reduction in HAE attacks recorded in Phase 3 trial results for lonvo-z, Intellia's one-time CRISPR gene editing therapy for hereditary angioedema.
• The data readout was accompanied by a Regulation FD Disclosure filed with the SEC on June 15, 2026, classifying the release as a material event.
• Lonvo-z is designed as a one-time therapy, positioning it against existing chronic treatment options in the HAE market, according to Benzinga reporting on the data.
• The Phase 3 results reinforced Intellia's regulatory outlook for the therapy, per Benzinga coverage of the readout.

Why It Matters

HAE is a rare, potentially life-threatening disorder characterized by recurrent episodes of severe swelling. An 87% reduction in attack frequency in a Phase 3 setting is a clinically meaningful result that directly supports a regulatory submission pathway. The one-time administration model differentiates lonvo-z from chronic suppression therapies, according to Benzinga's coverage of the data.

The June 15 SEC filing categorizing the data release as a material event underscores its significance to the company's development timeline. For Intellia, Phase 3 readouts of this scale represent a pivotal step toward potential commercialization of its CRISPR platform in rare disease.

Wall Street View

Wall Street is divided on NTLA following the data. Citizens analyst Silvan Turkcan reiterates a Market Outperform with a $30 price target, while HC Wainwright analyst Mitchell S. Kapoor maintains a Buy rating with a $25 target. Wedbush analyst David Nierengarten holds a Neutral stance with a $12 price target, reflecting meaningful disagreement on the risk-reward profile. The broader analyst consensus as of June 1, 2026 stood at 5 Strong Buy, 10 Buy, 11 Hold, and 2 Sell recommendations.

Investor Takeaway

The 87% HAE attack reduction in Phase 3 gives Intellia a concrete data package to advance lonvo-z toward regulators, a critical near-term catalyst for the company. The wide spread between Wedbush's $12 target and Citizens' $30 target captures the binary nature of the regulatory path ahead, and the outcome of that process will be the primary driver of long-term value for NTLA shareholders.